RCM
TGTX icon

Raleigh Capital Management’s TG Therapeutics TGTX Stock Holding History

Raleigh Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-54
Closed -$1.79K – 749
2026
Q1 		$1.79K Buy
+54
New +$1.61K ﹤0.01% 556
2025
Q1 		– Sell
-1,728
Closed -$52K – 1006
2024
Q4 		$52K Hold
1,728
– – 0.02% 312
2024
Q3 		$40.4K Hold
1,728
– – 0.02% 348
2024
Q2 		$30.7K Hold
1,728
– – 0.01% 367
2024
Q1 		$26.3K Buy
1,728
+300
+21% +$4.78K 0.01% 391
2023
Q4 		$24.4K Buy
1,428
+200
+16% +$2.32K 0.01% 401
2023
Q3 		$10.3K Buy
1,228
+63
+5% +$878 0.01% 509
2023
Q2 		$28.9K Hold
1,165
– – 0.01% 318
2023
Q1 		$17.5K Hold
1,165
– – 0.01% 396
2022
Q4 		$13.8K Buy
1,165
+200
+21% +$1.45K 0.01% 375
2022
Q3 		$6K Buy
965
+90
+10% +$590 ﹤0.01% 462
2022
Q2 		$4K Buy
875
+200
+30% +$1.25K ﹤0.01% 486
2022
Q1 		$6K Buy
+675
New +$7.81K ﹤0.01% 439

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Raleigh Capital Management's TGTX Position: Q2 2026 in Review

Raleigh Capital Management sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 54 shares — an estimated $1.79K sold.

Raleigh Capital Management first reported a position in TGTX in Q1 2022 and held it in 13 quarters. The position peaked at $52K in Q4 2024. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Raleigh Capital Management reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raleigh Capital Management sold 54 TG Therapeutics shares in Q2 2026, an estimated $1.79K.
  • Raleigh Capital Management first reported a position in TG Therapeutics in Q1 2022 and held it in 13 quarters.
  • Raleigh Capital Management's TG Therapeutics position peaked at $52K in Q4 2024.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.